Evogene Ltd. EVGN
Regular-session close
After hours · Nov 20, 4:00 PM ET
- YTD
- -71.25%
- 1 year
- -70.72%
5D -0.0811 (-21.20%)
- Market cap
- 5.71M
- Revenue (ttm)
- 9.45M
- Profit margin
- -210.25%
- EPS (ttm)
- -1.55
- Shares out
- 6.79M
- Forward P/E
- -0.39
- YTD return
- -71.25%
- 1-year return
- -70.72%
- Volume
- 62.77K
- Avg volume
- 1.42M
- Open
- 0.31
- Previous close
- 0.313
- Day's range
- 0.2891 – 0.341
- 52-week range
- 0.27 – 1.15
- Beta
- 1.08
- Price target
- 8.13 (+2469.6%)
Key statistics
- 50-day average
- 1.87
- 200-day average
- 4.76
- Enterprise value
- 5.18M
- Price / sales
- 0.97
- Price / book
- 0.57
- Revenue growth
- 39.80%
- Free cash flow
- -2.42M
- Total cash
- 20.91M
- Total debt
- 810.00K
- Return on equity
- -82.37%
- Short % of float
- 0.42%
Fundamental scorecard
5 of 25 checks passed on EVGN’s reported financials
5of 25 checks passed
- Value 1 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend No data
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 21, 2024 | Sep 1, 2024 | 0.00 | -1.31 | — | — |
| Aug 22, 2024 | Jun 1, 2024 | 0.00 | -1.06 | — | — |
| May 23, 2024 | Mar 1, 2024 | 0.00 | -0.80 | — | — |
| Mar 7, 2024 | Dec 1, 2023 | -1.40 | -1.30 | +0.10 | +7.14% |
| Nov 15, 2023 | Sep 1, 2023 | -1.70 | -0.80 | +0.90 | +52.94% |
| Aug 17, 2023 | Jun 1, 2023 | -1.90 | -1.70 | +0.20 | +10.53% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 23, 2024 | Lake Street | main | Buy | Buy |
| Oct 2, 2023 | Alliance Global Partners | init | — | Buy |
| Aug 18, 2023 | Lake Street | main | Buy | Buy |
| Jul 21, 2023 | Roth MKM | main | Buy | Buy |
| May 2, 2023 | Lake Street | init | — | Buy |
| Sep 12, 2022 | Aegis Capital | main | — | Buy |
About Evogene Ltd.
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health, agriculture, and other industrial applications through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, gastrointestinal inflammatory related disorders, and antimicrobial resistance organisms. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- Website
- evogene.com
News
12 Health Care Stocks Moving In Thursday's After-Market Session
EverGen Infrastructure Corp. (EVGN:CA) Q3 2026 Earnings Call Transcript
Evogene Ltd. (EVGN) Q3 2026 Earnings Call Transcript UPDATE: Evogene Q3 EPS Cont Operations $(0.17) Beats $(0.19) Estimate
Evogene Q3 EPS $(0.00) Beats $(0.19) Estimate, Sales $141.000K Miss $365.000K Estimate
Evogene Reports Financial Results for the Third Quarter and First Nine Months of 2026, Highlighting Progress in Two Internal Development Programs
EverGen Infrastructure Reports Q3 2026 Improved Results Evogene Unit AgPlenus Announces Progress In Two Fungicide Discovery Programs Targeting Wheat Disease Septoria Tritici Blotch
AgPlenus Announces Significant Progress in Its Fungicide Discovery Programs Targeting New Modes of Action, with Activity Against Resistant Septoria and Additional Fungal Pathogens
Coya Therapeutics (NASDAQ:COYA) vs. Evogene (NASDAQ:EVGN) Head to Head Review
Your note
Sign in to keep a note on EVGN — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SilverArc Capital Management, LLC | 0.61% | 308,550 | 416.54K | Mar 30, 2024 |
| Morgan Stanley | 0.06% | 28,404 | 38.34K | Mar 30, 2024 |
| BNP Paribas Financial Markets | 0.02% | 9,140 | 12.34K | Mar 30, 2024 |
| LPL Financial LLC | 0.01% | 6,684 | 9.02K | Mar 30, 2024 |
| JP Morgan Chase & Company | 0.01% | 3,943 | 5.32K | Mar 30, 2024 |
| UBS Group AG | 0.01% | 6,250 | 8.44K | Mar 30, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.01% | 5,901 | 7.97K | May 30, 2024 |
